NASDAQ:NURO - NeuroMetrix Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$3.70
▲ +0.1 (2.78%)

This chart shows the closing price for NURO by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New NeuroMetrix Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for NURO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for NURO

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for NeuroMetrix in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $3.70.

This chart shows the closing price for NURO for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 investment analysts is to n/a stock in NeuroMetrix. This rating has held steady since September 2020, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/1/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/31/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/29/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/27/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/26/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/26/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/25/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/24/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/18/2019HC WainwrightReiterated RatingBuy$5.00Low
4/26/2019HC WainwrightReiterated RatingBuy$5.00Low
12/26/2018HC WainwrightInitiated CoverageBuyHigh
10/20/2017HC WainwrightReiterated RatingBuy$10.00 ➝ $3.00N/A
6/15/2017HC WainwrightSet Price TargetBuy$16.00Low
10/23/2016HC WainwrightReiterated RatingBuy$36.00N/A
10/21/2016Rodman & RenshawReiterated RatingBuy$36.00N/A
9/15/2016HC WainwrightSet Price TargetBuy$36.00N/A
9/4/2016Rodman & RenshawSet Price TargetBuy$36.00N/A
7/22/2016Rodman & RenshawReiterated RatingBuyN/A
6/28/2016Rodman & RenshawInitiated CoverageBuy$36.00N/A
(Data available from 6/24/2016 forward)
NeuroMetrix logo
NeuroMetrix, Inc., a healthcare company, develops and markets products for the detection, diagnosis, and monitoring of peripheral nerve and spinal cord disorders. The company develops wearable neuro-stimulation therapeutic devices and point-of-care neuropathy diagnostic tests to address chronic health conditions, including chronic pain, sleep disorders, and diabetes. Its marketed products include Quell, a wearable device for relief of chronic intractable pain, such as nerve pain due to diabetes and lower back problems; DPNCheck, a test used to evaluate systemic neuropathies, such as diabetic peripheral neuropathy; ADVANCE system, a platform for the performance of traditional nerve conduction studies; and SENSUS, a pain therapy device based on transcutaneous electrical nerve stimulation for relief of chronic intractable pain. The company offers its products to consumers, retail merchandisers, direct response TV promoters, health care professionals, managed care organizations, endocrinologists, podiatrists, physicians, neurologists, and physical medicine and rehabilitation centers, as well as primary care, internal medicine, orthopedic, hand, and neurosurgeons. It operates in the United States, Europe, Japan, China, the Middle East, and Mexico. The company has a strategic collaboration with GlaxoSmithKline. NeuroMetrix, Inc. was founded in 1996 and is based in Woburn, Massachusetts.
Read More

Today's Range

Now: $3.70
Low: $3.69
High: $3.70

50 Day Range

MA: $3.11
Low: $2.72
High: $3.80

52 Week Range

Now: $3.70
Low: $1.39
High: $5.78

Volume

274 shs

Average Volume

224,065 shs

Market Capitalization

$14.07 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.79

Frequently Asked Questions

What sell-side analysts currently cover shares of NeuroMetrix?

The following sell-side analysts have issued reports on NeuroMetrix in the last twelve months:
View the latest analyst ratings for NURO.

What is the current price target for NeuroMetrix?

0 Wall Street analysts have set twelve-month price targets for NeuroMetrix in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for NeuroMetrix in the next year.
View the latest price targets for NURO.

What is the current consensus analyst rating for NeuroMetrix?

NeuroMetrix currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for NURO.

What other companies compete with NeuroMetrix?

How do I contact NeuroMetrix's investor relations team?

NeuroMetrix's physical mailing address is 4B GILL STREET WOBURN, MASSACHUSETTS MA, 01801. The medical device company's listed phone number is 781-890-9989 and its investor relations email address is [email protected] The official website for NeuroMetrix is www.neurometrix.com.